重组人脑利钠肽辅助治疗老年失代偿性心力衰竭的效果

Effect of Recombinant Human Brain Natriuretic Peptide as AdjuvantTherapy in Elderly Patients with Decompensated Heart Failure

目的:分析重组人脑利钠肽(rhBNP)辅助治疗老年失代偿性心力衰竭(DHF)的应用效果。方法:采用随机数字表法将96例老年DHF患者分为对照组和观察组,每组48例;对照组患者给予左西孟旦治疗,观察组使用rhBNP进行辅助治疗;观察两组患者临床治疗效果、血清指标[血清和肽素、N末端B型脑钠肽前体(NT-proBNP)、内皮素(ET-1)]变化、心功能[左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、左心室射血分数(LVEF)、心输出量]情况及不良反应发生情况。结果:观察组临床治疗总有效率(91.67%)高于对照组(75.00%)(P<0.05);治疗后,两组患者血清和肽素、NT-proBNP、ET-1水平均较治疗前降低,且观察组低于对照组(P<0.05);两组患者LVEDD、LVESD水平均较治疗前降低,且观察组低于对照组(P<0.05);两组患者LVEF、心输出量水平均较治疗前升高,且观察组高于对照组(P<0.05);两组不良反应发生率无统计学差异(P>0.05)。结论:rhBNP辅助治疗老年DHF可以提高患者的临床疗效,改善心功能和预后情况,且不良反应无明显增加。

Objective:To analyze the application effect of recombinant human brain natriuretic peptide(rhBNP)as adjuvant therapy in elderly patients with decompensated heart failure(DHF).Methods:A total of 96 elderly patients with DHF were randomly divided into a control group and an observation group,with 48 patients in each group.Patients in the control group were treated with levosimendan,while those in the observation group received adjuvant therapy with rhBNP.Clinical treatment outcomes,changes in serum markers(copeptin,N-terminal pro-B-type natriuretic peptide(NT-proBNP),and endothelin-1(ET-1)),cardiac function(left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),and cardiac output),and adverse reactions were observed in both groups.Results:The total effective rate of clinical treatment in the observation group(91.67%)was higher than that in the control group(75.00%)(P<0.05).After treatment,the levels of serum copeptin,NT-proBNP,and ET-1 were lower in both groups compared to before treatment,and the levels in the observation group were lower than those in the control group(P<0.05).The LVEDD and LVESD levels were lower in both groups after treatment compared to before,and the levels in the observation group were lower than those in the control group(P<0.05).The LVEF and cardiac output levels were higher in both groups after treatment compared to before,and the levels in the observation group were higher than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Adjuvant therapy with rhBNP in elderly patients with DHF can improve clinical efficacy,cardiac function,and prognosis,without significantly increasing adverse reactions.